Adicet Bio (ACET) Net Cash Flow (2017 - 2026)
Adicet Bio (ACET) posted quarterly Net Cash Flow of -$2.7 million for Q1 2026, up 90.56% year-over-year from -$1.4 million in Q1 2025, and down 127.34% quarter-over-quarter from $9.8 million in Q4 2025.
Adicet Bio (ACET) Net Cash Flow (2017 - 2026) Analysis & Trends
Adicet Bio's Net Cash Flow history runs 10 years deep, the most recent figure standing at -$2.7 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 90.56% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at $8.1 million (up 103.73% YoY), while the FY2025 annual figure was -$17.6 million, up 82.45% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$2.7 million, down from $9.8 million in the prior quarter.
- The five-year high for Net Cash Flow was $87.9 million in Q1 2024, with the low at -$118.6 million in Q3 2024.
- The 5-year median for Net Cash Flow is -$22.2 million (2023), against an average of -$14.0 million.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow tumbled 7774.34% in 2023, then soared 437.78% in 2024.
- Adicet Bio's Net Cash Flow stood at -$25.0 million in 2022, then grew by 5.9% to -$23.5 million in 2023, then tumbled by 95.72% to -$46.1 million in 2024, then soared by 121.24% to $9.8 million in 2025, then tumbled by 127.34% to -$2.7 million in 2026.
- Business Quant data shows ACET's Net Cash Flow at -$2.7 million in Q1 2026, $9.8 million in Q4 2025, and -$5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 225.59 Mn |
| 10 | Adicet Bio | 98.64 Mn | -19.55 Mn | - | -3.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.11 Mn |
| Jun 30, 2026 | -3.11 Mn |
| Mar 31, 2026 | -2.68 Mn |
| Mar 31, 2026 | -2.68 Mn |
| Dec 31, 2025 | 9.79 Mn |
| Dec 31, 2025 | 9.79 Mn |
| Sep 30, 2025 | -5.62 Mn |
| Sep 30, 2025 | -5.62 Mn |
| Jun 30, 2025 | 6.59 Mn |
| Jun 30, 2025 | 6.59 Mn |
| Mar 31, 2025 | -28.36 Mn |
| Mar 31, 2025 | -28.36 Mn |
| Dec 31, 2024 | -46.08 Mn |
| Dec 31, 2024 | -46.08 Mn |
| Sep 30, 2024 | -118.59 Mn |
| Sep 30, 2024 | -118.59 Mn |
| Jun 30, 2024 | -23.52 Mn |
| Jun 30, 2024 | -23.52 Mn |
| Mar 31, 2024 | 87.88 Mn |
| Mar 31, 2024 | 87.88 Mn |